Andrew J Miller1, Edwin A Takahashi2, William S Harmsen3, Kristin C Mara4, Sanjay Misra5. 1. Department of Radiology, Mayo Clinic, Rochester, Minnesota; Division of Vascular and Interventional Radiology, Mayo Clinic, Rochester, Minnesota. 2. Department of Radiology, Mayo Clinic, Rochester, Minnesota. 3. Department of Radiology, Mayo Clinic, Rochester, Minnesota; Department of Clinical Statistics, Mayo Clinic, Rochester, Minnesota. 4. Department of Clinical Statistics, Mayo Clinic, Rochester, Minnesota. 5. Department of Radiology, Mayo Clinic, Rochester, Minnesota; Division of Vascular and Interventional Radiology, Mayo Clinic, Rochester, Minnesota. Electronic address: misra.sanjay@mayo.edu.
Abstract
PURPOSE: To determine the predictors of restenosis, major adverse limb events (MALEs), postoperative death (POD), and all-cause mortality after repeat endovascular treatment of superficial femoral artery (SFA) restenosis. MATERIALS AND METHODS: This was a retrospective review of 440 patients with 518 SFA lesions who were treated between January 2002 and October 2011. Ninety-six limbs were treated for restenosis with bare metal stents (BMSs) or percutaneous transluminal angioplasty (PTA), of which 28 limbs developed another restenosis requiring a third procedure. The interaction measured in this study was between the second and third intervention. Predictors of SFA patency, MALEs, POD, and all-cause mortality after SFA restenosis treatment were identified. RESULTS: Patients who were treated with BMSs (n = 51) had similar rates of restenosis compared with patients who were treated with PTA (n = 45) (hazard ratio [HR] 1.40; 95% confidence interval [CI] 0.68-2.90; P = .37). Patients in the BMS group who took statins had a significantly lower risk of restenosis than patients who did not take statins (HR 0.13; 95% CI 0.04-0.41; P < .001). Stage 4-5 chronic kidney disease (CKD) (n = 12) was associated with a significantly higher risk of MALE + POD (HR 6.17; 95% CI 1.45-26.18; P = .014) and all-cause mortality (HR 2.83; 95% CI 1.27-6.33; P = .01). Clopidogrel was protective against all-cause mortality (HR 0.41; 95% CI 0.20-0.80; P = .01). CONCLUSIONS: Patients in the BMS group who took statins at the time of intervention had a significantly lower risk of developing restenosis. Stage 4-5 CKD was a risk factor for MALE + POD and all-cause mortality, while clopidogrel decreased all-cause mortality risk.
PURPOSE: To determine the predictors of restenosis, major adverse limb events (MALEs), postoperative death (POD), and all-cause mortality after repeat endovascular treatment of superficial femoral artery (SFA) restenosis. MATERIALS AND METHODS: This was a retrospective review of 440 patients with 518 SFA lesions who were treated between January 2002 and October 2011. Ninety-six limbs were treated for restenosis with bare metal stents (BMSs) or percutaneous transluminal angioplasty (PTA), of which 28 limbs developed another restenosis requiring a third procedure. The interaction measured in this study was between the second and third intervention. Predictors of SFA patency, MALEs, POD, and all-cause mortality after SFA restenosis treatment were identified. RESULTS:Patients who were treated with BMSs (n = 51) had similar rates of restenosis compared with patients who were treated with PTA (n = 45) (hazard ratio [HR] 1.40; 95% confidence interval [CI] 0.68-2.90; P = .37). Patients in the BMS group who took statins had a significantly lower risk of restenosis than patients who did not take statins (HR 0.13; 95% CI 0.04-0.41; P < .001). Stage 4-5 chronic kidney disease (CKD) (n = 12) was associated with a significantly higher risk of MALE + POD (HR 6.17; 95% CI 1.45-26.18; P = .014) and all-cause mortality (HR 2.83; 95% CI 1.27-6.33; P = .01). Clopidogrel was protective against all-cause mortality (HR 0.41; 95% CI 0.20-0.80; P = .01). CONCLUSIONS:Patients in the BMS group who took statins at the time of intervention had a significantly lower risk of developing restenosis. Stage 4-5 CKD was a risk factor for MALE + POD and all-cause mortality, while clopidogrel decreased all-cause mortality risk.
Authors: Roswitha M Wolfram; Alexandra C Budinsky; Boris Pokrajac; Richard Potter; Erich Minar Journal: Radiology Date: 2005-06-13 Impact factor: 11.105
Authors: Gregory G Westin; Ehrin J Armstrong; Heejung Bang; Khung-Keong Yeo; David Anderson; David L Dawson; William C Pevec; Ezra A Amsterdam; John R Laird Journal: J Am Coll Cardiol Date: 2013-12-04 Impact factor: 24.094
Authors: P J Matsi; H I Manninen; R L Vanninen; M T Suhonen; I Oksala; M Laakso; T Hakkarainen; S Soimakallio Journal: Radiology Date: 1994-06 Impact factor: 11.105
Authors: Wonho Kim; Ripal T Gandhi; Constantino S Peña; Raul E Herrera; Melanie B Schernthaner; Juan M Acuña; Victor N Becerra; Barry T Katzen Journal: J Vasc Interv Radiol Date: 2016-08-10 Impact factor: 3.464
Authors: Andres Schanzer; Nathanael Hevelone; Christopher D Owens; Joshua A Beckman; Michael Belkin; Michael S Conte Journal: J Vasc Surg Date: 2008-04 Impact factor: 4.268